MedTrace Logo

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

NCT06007937 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2026-04-08

No results posted yet for this study

Summary

This study will test the safety of the combination of ramucirumab and lorlatinib. The researchers will test one or two different doses of lorlatinib in combination with ramucirumab to find the drug combination dose that causes few or mild side effects in participants. Once the researchers find this dose, they can test it in future participants to see if it is effective in treating their metastatic ALK-rearranged NSCLC. The researchers are also looking to see whether there are specific genes or DNA sequences associated with a response to treatment with lorlatinib and ramucirumab.

Conditions

  • Non Small Cell Lung Cancer
  • Metastatic
  • Recurrent

Interventions

DRUG

Lorlatinib

Lorlatinib 100 mg orally daily

DRUG

Ramucirumab

Ramucirumab 10 mg/kg intravenous infusion once every three weeks is a tolerable and safe dose.

Sponsors & Collaborators

Principal Investigators

  • Gregory Riely, MD, PhD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-17
Primary Completion
2028-08-17
Completion
2028-08-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06007937 on ClinicalTrials.gov